Skip to main content

Newsroom press releases

29/01/26 - 7:03

Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
Products Immunodiagnostic
Download

27/01/26 - 16:05

The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
Other
Download

26/01/26 - 7:09

Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
Products Molecular
Download

23/01/26 - 17:49

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
Other
Download

29/12/20 - 18:22

DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
Products Molecular
Download

17/12/20 - 17:57

DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics (298.96 KB)
Other
Download

07/12/20 - 10:35

Communication on total amount of voting rights (563.18 KB)
Other
Download

04/12/20 - 16:14

Form 3F (November 2020) (10.2 KB)
Other
Download

01/12/20 - 6:33

DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
Products Immunodiagnostic
Download

11/11/20 - 12:41

North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
Financial Data
Download

26/10/20 - 18:30

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
Products Immunodiagnostic
Download

23/10/20 - 19:41

Conclusion treasury shares buy-back plan (314.28 KB)
Other
Download

23/10/20 - 19:37

Weekly report treasury shares buy-back (436.92 KB)
Other
Download

16/10/20 - 18:28

Weekly report treasury shares buy-back (425.19 KB)
Other
Download

01/10/20 - 7:45

DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
Products Immunodiagnostic
Download

01/10/20 - 7:32

DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
Products Immunodiagnostic
Download

23/09/20 - 7:16

DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China (495.78 KB)
Acquisition / Partnership
Download

16/09/20 - 14:30

Update Annual Calendar of Corporate Events 2020 (222.26 KB)
Other
Download

16/09/20 - 7:25

DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
Products Molecular
Download

08/09/20 - 7:31

DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution (506.16 KB)
Acquisition / Partnership
Download

07/09/20 - 18:22

FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
Products Molecular
Download

06/08/20 - 7:25

DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
Products Immunodiagnostic
Download

31/07/20 - 16:04

Weekly report treasury shares buy-back (380.16 KB)
Other
Download

30/07/20 - 13:16

North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
Financial Data
Download

24/07/20 - 17:19

Weekly report treasury shares buy-back (363.73 KB)
Other
Download

17/07/20 - 18:19

Weekly report treasury shares buy-back (360.09 KB)
Other
Download

10/07/20 - 18:23

Weekly report treasury shares buy-back (374 KB)
Other
Download

09/07/20 - 7:27

DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
Products Immunodiagnostic
Download

07/07/20 - 7:22

DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
Products Molecular
Download

30/06/20 - 7:25

DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
Products Immunodiagnostic
Download

19/06/20 - 17:20

Weekly report treasury shares buy-back (399.38 KB)
Other
Download

17/06/20 - 16:09

Start up of the treasury shares buy-back plan (481.28 KB)
Other
Download

12/06/20 - 7:30

DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
Products Molecular
Download

10/06/20 - 15:40

Shareholders' Meeting June 10, 2020 (308.25 KB)
Other
Download

03/06/20 - 14:16

The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
Products Immunodiagnostic
Download

02/06/20 - 14:58

Communication total amount voting rights (record date) (267.83 KB)
Download

18/05/20 - 11:28

The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
Products Immunodiagnostic
Download

13/05/20 - 13:15

DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
Financial Data
Download

25/04/20 - 16:49

DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
Products Immunodiagnostic
Download

17/04/20 - 18:25

DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
Products Immunodiagnostic
Download

07/04/20 - 7:14

IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
Products Immunodiagnostic
Download

26/03/20 - 18:14

Update Annual Calendar of Corporate Events 2020 (277.25 KB)
Other
Download

21/03/20 - 20:29

Shareholders' Meeting date change (288.23 KB)
Other
Download

20/03/20 - 7:28

DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
Products Molecular
Download

13/03/20 - 17:16

DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
Products Molecular
Download

11/03/20 - 13:43

DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
Financial Data
Download

10/03/20 - 8:20

DiaSorin - Development of Coronavirus test (404.03 KB)
Products Molecular
Download

02/03/20 - 8:04

DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology (396.06 KB)
Acquisition / Partnership
Download

07/02/20 - 8:06

Communication on total amount of voting rights (281.13 KB)
Other
Download

15/01/20 - 16:51

Annual Calendar of Corporate Events 2020 (124.73 KB)
Other
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.